Show simple item record

dc.contributor.authorVagnildhaug, Ola Magne
dc.contributor.authorBlum, David
dc.contributor.authorWilcock, Andrew
dc.contributor.authorFayers, Peter
dc.contributor.authorStrasser, Florian
dc.contributor.authorBaracos, Vickie E.
dc.contributor.authorHjermstad, Marianne Jensen
dc.contributor.authorKaasa, Stein
dc.contributor.authorLaird, Barry J
dc.contributor.authorSolheim, Tora Skeidsvoll
dc.date.accessioned2017-11-16T07:54:26Z
dc.date.available2017-11-16T07:54:26Z
dc.date.created2017-11-15T13:24:00Z
dc.date.issued2017
dc.identifier.citationJournal of Cachexia, Sarcopenia and Muscle. 2017, 8 (5), 789-797.nb_NO
dc.identifier.issn2190-5991
dc.identifier.urihttp://hdl.handle.net/11250/2466546
dc.description.abstractBackground A body mass index (BMI) adjusted weight loss grading system (WLGS) is related to survival in patients with cancer. The aim of this study was to examine the applicability of the WLGS by confirming its prognostic validity, evaluating its relationship to cachexia domains, and exploring its ability to predict cachexia progression. Methods An international, prospective observational study of patients with incurable cancer was conducted. For each patient, weight loss grade was scored 0–4. Weight loss grade 0 represents a high BMI with limited weight loss, progressing through to weight loss grade 4 representing low BMI and a high degree of weight loss. Survival analyses were used to confirm prognostic validity. Analyses of variance were used to evaluate the relationship between the WLGS and cachexia domains [anorexia, dietary intake, Karnofsky performance status (KPS), and physical and emotional functioning]. Cox regression was used to evaluate if the addition of cachexia domains to the WLGS improved prognostic accuracy. Predictive ability of cachexia progression was assessed by estimating proportion of patients progressing to a more advanced weight loss grade. Results One thousand four hundred six patients were analysed (median age 66 years; 50% female, 63% KPS ≤ 70). The overall effect of the WLGS on survival was significant as expressed by change in −2 log likelihood (P < 0.001) and persisted after adjustment for age, sex, and cancer type and stage (P < 0.001). Median survival decreased across the weight loss grades ranging from 407 days (95% CI 312–502)—weight loss grade 0 to 119 days (95% CI 93–145)—weight loss grade 4. All cachexia domains significantly deteriorated with increasing weight loss grade, and deterioration was greatest for dietary intake, with a difference corresponding to 0.87 standard deviations between weight loss grades 0 and 4. The addition of KPS, anorexia, and physical and emotional functioning improved the prognostic accuracy of the WLGS. Likelihood of cachexia progression was greater in patients with weight loss grade 2 (39%) than that with weight loss grade 0 (19%) or 1 (22%). Conclusions The WLGS is related to survival, cachexia domains, and the likelihood of progression. Adding certain cachexia domains to the WLGS improves prognostic accuracy.nb_NO
dc.language.isoengnb_NO
dc.publisherWiley Open Accessnb_NO
dc.relation.urihttp://onlinelibrary.wiley.com/doi/10.1002/jcsm.12220/full
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleThe applicability of a weight loss grading system in cancer cachexia: a longitudinal analysisnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber789-797nb_NO
dc.source.volume8nb_NO
dc.source.journalJournal of Cachexia, Sarcopenia and Musclenb_NO
dc.source.issue5nb_NO
dc.identifier.doi10.1002/jcsm.12220
dc.identifier.cristin1514407
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU: 90062500nb_NO
dc.description.localcode© 2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are madenb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal